Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients.

Louw, G E; Warren, R M; Donald, P R; Murray, M B; Bosman, M; Van Helden, P D; Young, D B; Victor, T C

Louw, G E; Warren, R M; Donald, P R; Murray, M B; Bosman, M; Van Helden, P D; Young, D B; Victor, T C.

Affiliation

Louw GE; Department of Biomedical Sciences, Division of Molecular Biology and Human Genetics, Faculty of Health Sciences, Stellenbosch University, Tygerberg, South Africa.

Int J Tuberc Lung Dis ; 10(7): 802-7, 2006 Jul.

Article in En | MEDLINE | ID: mdl-16848344

Subject(s)

Antitubercular Agents/therapeutic use; Drug Resistance, Microbial; Pyrazinamide/therapeutic use; Tuberculosis/drug therapy; Antitubercular Agents/pharmacology; Base Sequence; DNA Primers; Drug Resistance, Microbial/genetics; Humans; Mutation; Mycobacterium tuberculosis/drug effects; Mycobacterium tuberculosis/genetics; Polymerase Chain Reaction; Pyrazinamide/pharmacology

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pyrazinamide / Tuberculosis / Drug Resistance, Microbial / Antitubercular Agents Limits: Humans Language: En Journal: Int J Tuberc Lung Dis Year: 2006 Type: Article Affiliation country: South Africa

Search on Google

XML

PubMed Links